JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - TWIST BIOSCIENCE CORP
Financial Performance:
- FY2026 (ended Sept 2026) revenue grew 175% YoY to $59 million, up from $21 million in FY2025.
- FY2026 total company revenue reached $459 million; FY2027 revenue guidance is set at $550–$560 million.
- AI-driven drug discovery segment generated $59 million in 2026, with FY2027 guidance of at least $100 million (indicating potential for >70% growth if capacity constraints are resolved).
- The company achieved EBITDA break-even for the first time in the most recent quarter.
- Capital expenditure (CapEx) guidance for the next two years is $150 million ($75 million in 2026, $75 million in 2027) to fund capacity expansion.
Guidance and Future Outlook:
- Full-year 2027 revenue is guided at $550–$560 million, reflecting a ~20% compound annual growth rate.
- AI drug discovery revenue is guided at a minimum of $100 million for 2027, with management expecting potential upside if capacity ramp-up outpaces the current guide.
- Management anticipates significant upside drivers in NGS expansion, Minimal Residual Disease (MRD), and a rebound in academic/government funding, though these are not fully baked into the base guide.
- Long-term Total Addressable Market (TAM) expansion: from $2 billion in 2021 to $7 billion in 2026, with a line of sight to $13 billion.
- Future revenue models are shifting from lumpy pilot orders to recurring, predictable "turning the crank" production revenue for AI clients.
Business Segments and Product Lines:
- AI Drug Discovery: Core growth engine; customers progress from pilot orders ($10k–$100k) to model building (thousands of sequences) and finally production (recurring revenue).
- Cell-Free Synthesis: Launched globally two weeks prior to the call; unique capability to produce both single-domain and multi-domain proteins at scale, offering faster turnaround (weeks vs. months) than cell-based methods despite slightly lower data richness.
- MRD (Minimal Residual Disease): Identified as the next growth leg in the NGS franchise; requires thousands of probes (vs. 16 previously), leveraging Twist's high-volume silicon chip platform to capture high-sensitivity testing demand.
- NGS & Gene Synthesis: Maintained >20% growth in Q4; expanding into pooled discovery to reduce cost-per-data-point significantly compared to traditional arrayed methods.
- Product Evolution: Moving customers up the modality value chain from single-domain proteins (VHH) to complex multi-domain and multi-specific IgGs, increasing data point requirements and revenue per target.
Market and Competitive Landscape:
- AI Discovery: Highly competitive but fragmented; Twist serves diverse customers including top-5 pharma (e.g., Eli Lilly) and AI-native biotechs.
- Market Share Gains: Aggressively taking share in tough economic conditions by offering a value proposition of high quality, speed, and best-in-class pricing.
- Differentiation: Twist claims unique ability to manufacture pooled DNA at scale, quality, and speed that competitors cannot match, enabling lower costs for customers.
- Capacity: Currently operating 10 "riders" (DNA synthesis units), with orders placed to expand to 16 in the coming year.
Risks and Challenges:
- Capacity Constraints: The primary limiter on realizing AI revenue beyond the $100 million guide; significant lead times for adding synthesis "riders" and lab automation.
- Execution Risk: Scaling operations requires managing software integration and "cake eating" (execution discipline) rather than technical R&D risk, which is deemed minimal.
- Customer Concentration: Early AI revenue relied on a few cohorts, though this is diversifying into broader pharma adoption.
- Market Volatility: Academic and government funding remains under pressure, though Twist views itself as a supplier of choice during downturns due to value-driven switching.
Management Commentary and Tone:
- Tone: Highly confident and aggressive regarding growth, particularly in AI and capacity expansion.
- Strategy: Emphasis on a "foundry model" where minimizing viable costs through miniaturization drives volume.
- Customer Lifecycle: Management detailed a clear three-phase customer journey (Pilot -> Model Building -> Production) that validates the transition to recurring revenue.
- Talent: Cited a "sense of urgency" and high employee engagement as key competitive advantages.
Analyst Questions and Answers:
- Q: How should we think about upside drivers beyond the 20% base guide? A: Upside exists in NGS/MRD expansion, academic market rebound, and AI capacity additions.
- Q: How does AI revenue flow evolve over the year? A: Starts as lumpy pilot orders, transitions to large batch model-building data delivery, and stabilizes into recurring production revenue.
- Q: What is the technical risk in scaling protein synthesis? A: Minimal technical risk; strategy involves "copy-pasting" existing validated instruments and software integration.
- Q: How does cell-free compare to cell-based synthesis? A: Cell-free is weeks faster and suitable for high-throughput screening, though it provides less data richness and volume than cell-based, which remains needed for full development datasets.
- Q: What is the outlook for MRD and competition with Natera? A: Natera established the market; Twist's advantage lies in the supply of thousands of high-sensitivity probes required for next-generation testing.
Other Key Points:
- Technology Base: Proprietary "silicon chip" technology miniaturized DNA synthesis from 96-well plate format (96 oligos) to one million oligos per footprint.
- Cost Structure: High fixed costs but very low variable costs due to miniaturization, favoring a high-volume foundry business model.
- Innovation Engine: Continuous product introduction to expand DNA "flavors" and support new applications like antibody discovery and protein diagnostics.
- Industry Shift: AI drug discovery is moving from dry-lab design to wet-lab "build and test" outsourcing, a gap Twist is filling.
- Company
- TWIST BIOSCIENCE CORP
- Keywords
- TWIST BIOSCIENCE CORP